A PHASE 1, OPEN LABEL, FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS

This is a Phase 1, open label, fixed sequence study of the effect of multiple dose PF-06650833 on single dose OC PK in healthy female subjects.

Start Date08 Oct 2021

Sponsor / Collaborator

Pfizer Inc.

NCT04933799

/ Unknown statusPhase 2IIT

A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Trial Assessing the Efficacy and Safety of PF-06650833 in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

The aim of the current clinical study is to evaluate the efficacy and safety of inhibition of Interleukin-1 receptor associated kinase 4 (IRAK4) in ameliorating the proinflammatory state and improving outcomes in severe COVID-19.

Start Date06 Jan 2021

Sponsor / Collaborator

Bronx-Lebanon Hospital Center Health Care System

[+1]

NCT04575610

/ TerminatedPhase 2IIT

Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)

The purpose of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19.

Start Date27 Nov 2020

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Zimlovisertib

100 Translational Medicine associated with Zimlovisertib

100 Patents (Medical) associated with Zimlovisertib

Literatures (Medical) associated with Zimlovisertib

01 Jul 2024·EXPERIMENTAL NEUROLOGY

Inhibiting the IRAK4/NF-κB/NLRP3 signaling pathway can reduce pyroptosis in hippocampal neurons and seizure episodes in epilepsy

Article

Author: Cui, Xiaoxiao ; Li, Lei ; Zhang, Xuefei ; Chen, Yanan ; Zhao, Ting ; Han, Xiong ; Cao, Jing ; Sun, Lei ; Wang, Na ; Zhang, Jiewen ; Su, Songxue ; Zhao, Jianyuan

BACKGROUND:

Interleukin-1 receptor-associated kinase 4 (IRAK4) plays an important role in immune modulation in various central nervous system disorders. However, IRAK4 has not been reported in epilepsy models in animal and clinical studies, nor has its involvement in regulating pyroptosis in epilepsy.

METHOD:

First, we performed transcriptome sequencing, quantitative real-time polymerase chain reaction, and western blot analysis on the hippocampal tissues of refractory epilepsy patients to measure the mRNA and protein levels of IRAK4 and pyroptosis-related proteins. Second, we successfully established a pentylenetetrazol (PTZ)-induced seizure mouse model. We conducted behavioral tests, electroencephalography, virus injection, and molecular biology experiments to investigate the role of IRAK4 in seizure activity regulation.

RESULTS:

IRAK4 is upregulated in the hippocampus of epilepsy patients and PTZ-induced seizure model mice. IRAK4 expression is observed in the hilar neurons of PTZ-induced mice. Knocking down IRAK4 in PTZ-induced mice downregulated pyroptosis-related protein expression and alleviated seizure activity. Overexpressing IRAK4 in naive mice upregulated pyroptosis-related protein expression and increased PTZ-induced abnormal neuronal discharges. IRAK4 and NF-κB were found to bind to each other in patient hippocampal tissue samples. Pyrrolidine dithiocarbamate reversed the pyroptosis-related protein expression increase caused by PTZ. PF-06650833 alleviated seizure activity and inhibited pyroptosis in PTZ-induced seizure mice.

CONCLUSION:

IRAK4 plays a key role in the pathological process of epilepsy, and its potential mechanism may be related to pyroptosis mediated by the NF-κB/NLRP3 signaling pathway. PF-06650833 has potential as a therapeutic agent for alleviating epilepsy.

01 Jun 2024·NATURE IMMUNOLOGY

Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus

Article

Author: Gao, Xia ; Lan, Chaoting ; Idiiatullina, Elina ; Li, Xiaotian ; Chen, Jiazhang ; Masters, Seth L ; Zeng, Ping ; Liu, Ziyang ; Liu, Yunfeng ; Lu, Bingtai ; Xian, Huifang ; Zhou, Wenhao ; Guo, Caiqin ; Lin, Meng ; Zhu, Jianheng ; Cui, Jun ; Liu, Yiyi ; Zhang, Yuxia ; Chang, Jingjie ; Wu, Qi ; Yang, Mandy ; Zhao, Zhiyao ; Zhang, Yan ; Al-Azab, Mahmoud ; Hrovat-Schaale, Katja

Abstract:

Rare genetic variants in toll-like receptor 7 (TLR7) are known to cause lupus in humans and mice. UNC93B1 is a transmembrane protein that regulates TLR7 localization into endosomes. In the present study, we identify two new variants in UNC93B1 (T314A, located proximally to the TLR7 transmembrane domain, and V117L) in a cohort of east Asian patients with childhood-onset systemic lupus erythematosus. The V117L variant was associated with increased expression of type I interferons and NF-κB-dependent cytokines in patient plasma and immortalized B cells. THP-1 cells expressing the variant UNC93B1 alleles exhibited exaggerated responses to stimulation of TLR7/-8, but not TLR3 or TLR9, which could be inhibited by targeting the downstream signaling molecules, IRAK1/-4. Heterozygous mice expressing the orthologous Unc93b1V117L variant developed a spontaneous lupus-like disease that was more severe in homozygotes and again hyperresponsive to TLR7 stimulation. Together, this work formally identifies genetic variants in UNC93B1 that can predispose to childhood-onset systemic lupus erythematosus.

11 Apr 2024·ACS medicinal chemistry letters

In Retrospect: Root-Cause Analysis of Structure–Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833)

Article

Author: Wright, Stephen W. ; Han, Seungil ; Farley, Kathleen A. ; Knafels, John D. ; Lee, Katherine L.

In this paper, we disclose insights on the root causes of three structure-activity relationship (SAR) observations encountered in the discovery of the IRAK4 inhibitor Zimlovisertib (PF-06650833). The first is a nonlinear potency SAR encountered with the isoquinoline ether substituent, the second is a potency enhancement introduced by fluorine substitution on the lactam, and the third is a slight potency preference for all-syn (2S,3S,4S) stereochemistry in the fluorine-substituted lactam. We present new data that help to inform us of the origins of these unexpected SAR trends.

News (Medical) associated with Zimlovisertib

22 Sep 2023

·synapse.patsnap.com

New Treatment Option for Inflammatory Diseases - IRAK4 inhibitors

Interleukin-1 receptor-associated kinases (IRAKs) were initially identified as serine/threonine kinases that can bind to the interleukin-1 receptor (IL-1R) upon induction by the pro-inflammatory cytokine interleukin-1 (IL-1). Later, these proteins were found to have high homology with the pelle kinases vital for resisting microbial infection in Drosophila Toll-like receptor (TLR) pathways. There are four members in the IRAK family: IRAK1, IRAK2, IRAK 4, and IRAK–M. All four IRAKs have a kinase domain (KD) containing serine and threonine, and a conserved death domain (DD). Except for IRAK4, the other three IRAKs also have a long C-terminal domain (C-terminal Domain). Among them, IRAK1 and IRAK4 play a positive regulatory role in TLR-mediated signaling pathways, while IRAK2 and IRAK-M play a negative regulatory role. As for the function of IRAK4 in TLRs/IL-1R mediated signaling pathways, aside from the classical activation of downstream NF-κB and AP-1 transcription factors, inducing the expression of inflammatory cytokines, chemokines, other studies have found that overexpression of IRAK4 can enhance LPS induced NADPH oxidase activity, and trigger the signal transduction of downstream p38 MAPK. This extends the biological role of the IRAK4 molecule even further, from simply functioning in TLRs /IL-1R mediated signaling pathways to actively participating in the widespread regulation of cellular response networks. With its signaling complex formation impeded by the absence of functional IRAK4 due to mutation, inflammation signal propagation becomes flawed. As a result, IRAK4 can serve as an effective potential therapeutic target for inflammatory-related disease, tackling them by inhibiting inflammatory signal transduction through specific targeting of IRAK4. IRAK4 Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 20 Sep 2023, there are a total of 42 IRAK4 drugs worldwide, from 36 organizations, covering 38 indications, and conducting 49 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. Based on the analysis of the provided data, the current competitive landscape of target IRAK4 in the pharmaceutical industry is characterized by the involvement of multiple companies at different stages of development. Kymera Therapeutics, Inc., Bayer AG, and Gilead Sciences, Inc. are among the companies with the highest number of drugs in advanced stages of development. The indications for drugs targeting IRAK4 are diverse, including rheumatoid arthritis, dermatitis, atopic, and hidradenitis suppurativa, among others. Small molecule drugs and PROTACs are the most rapidly progressing drug types under this target. The United States, European Union, and China are the countries/locations with the highest development activity. China has shown progress in the development of drugs targeting IRAK4. Overall, the target IRAK4 presents a competitive landscape with potential for future development in various indications and drug types. IRAK4 inhibitors entering Phase II clinical research: EdecesertibEdecesertib is a small molecule drug that targets IRAK4, a protein involved in immune system signaling. It is being developed for the treatment of skin and musculoskeletal diseases as well as immune system diseases. The active indications for Edecesertib include lupus erythematosus, cutaneous, and systemic lupus erythematosus. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Currently, Edecesertib is in Phase 2 of clinical development. This means that the drug has already undergone initial testing for safety and efficacy in a small group of patients and is now being evaluated in a larger population to further assess its effectiveness and side effects. Lupus erythematosus is a chronic autoimmune disease that affects various parts of the body, including the skin, joints, kidneys, heart, and lungs. Cutaneous lupus erythematosus specifically refers to the form of the disease that primarily affects the skin. Systemic lupus erythematosus, on the other hand, affects multiple organs and can cause more severe symptoms. The development of Edecesertib as a potential treatment for lupus erythematosus, both cutaneous and systemic, is significant as there is currently no cure for this condition. Current treatment options mainly focus on managing symptoms and preventing flare-ups. Therefore, the introduction of a new drug that targets IRAK4 and potentially modulates the immune system response could provide a novel approach to managing lupus erythematosus. Additionally, Edecesertib's therapeutic areas also include skin and musculoskeletal diseases, which further expands its potential applications. Skin diseases encompass a wide range of conditions, such as psoriasis, eczema, and dermatitis, which can significantly impact a patient's quality of life. Musculoskeletal diseases, on the other hand, involve the bones, muscles, joints, and connective tissues, and include conditions like rheumatoid arthritis and osteoporosis. In summary, Edecesertib is a small molecule drug that targets IRAK4 and is being developed for the treatment of skin and musculoskeletal diseases, as well as immune system diseases such as lupus erythematosus. With its current status in Phase 2 clinical trials, Edecesertib shows promise as a potential therapeutic option for patients suffering from these conditions. Further research and development will be necessary to determine its safety and efficacy in larger patient populations. IRAK4 inhibitors entering Phase II clinical research: ZimlovisertibZimlovisertib is a small molecule drug that falls under the category of biomedicine. It specifically targets IRAK4, which is a protein involved in the immune response. The drug has shown potential in treating various therapeutic areas, including immune system diseases, infectious diseases, skin and musculoskeletal diseases, and respiratory diseases. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. In terms of active indications, Zimlovisertib has been identified as a potential treatment for COVID-19 and COVID-19 respiratory infections. This suggests that the drug may have antiviral properties and could be effective in combating the respiratory symptoms associated with the disease. Additionally, Zimlovisertib is being explored as a treatment for Hidradenitis Suppurativa, a chronic skin condition characterized by painful nodules and abscesses, as well as Rheumatoid Arthritis, an autoimmune disorder affecting the joints. The originator organization of Zimlovisertib is Pfizer Inc., a renowned pharmaceutical company known for its contributions to the development of innovative drugs. This association adds credibility to the drug's potential efficacy and safety. In terms of clinical development, Zimlovisertib has reached Phase 2 of clinical development globally. This indicates that the drug has undergone extensive preclinical testing and has shown promising results in early-stage clinical trials. However, it is important to note that the highest phase in China is still pending, suggesting that further regulatory approvals may be required before the drug can progress to advanced stages of development in the Chinese market. In summary, Zimlovisertib is a small molecule drug developed by Pfizer Inc. that targets IRAK4. It has shown potential in treating various therapeutic areas, including immune system diseases, infectious diseases, skin and musculoskeletal diseases, and respiratory diseases. The drug is actively being investigated for its efficacy in treating COVID-19, COVID-19 respiratory infections, Hidradenitis Suppurativa, and Rheumatoid Arthritis. With its current highest phase being Phase 2 globally, Zimlovisertib holds promise as a potential treatment option, pending further regulatory approvals in China.

31 Jan 2023

·www.fiercebiotech.com

Pfizer punts pair of orphan drugs amid rare disease R&D rethink

Pfizer is kicking recifercept to the curb along with PF-06755347, a recombinant Fc fusion protein. Pfizer, amid a rethink of its rare disease R&D strategy, has punted (PDF) a pair of orphan drug candidates from its clinical development pipeline in a cull that also narrowed the opportunities open to the near-approval JAK3/TEC inhibitor ritlecitinib. Recifercept is the most advanced rare disease candidate to become surplus to requirements in the latest pipeline update. The molecule is designed to bind to fibroblast growth factor isoforms and thereby act as a decoy that reduces FGFR3 signaling. Seeing that FGFR3 mutations drive inhibitory signaling in the rare disease achondroplasia, Pfizer made the condition its focus indication for recifercept development. The program looked to be on track late last year, when Pfizer began a pilot project to check the feasibility of constructing a concurrent external control for recifercept, but has now hit the skids. The termination of development comes weeks after Pfizer wrapped up a phase 2 trial of the long-term safety and efficacy of recifercept. Pfizer is kicking the candidate to the curb along with PF-06755347, a recombinant Fc fusion protein that is the product of a licensing agreement the Big Pharma formed with Gliknik in 2013. Gliknik received $15 million from Pfizer when the candidate entered phase 1 four years ago. PF-06755347 was in development as a treatment for primary immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy, an indication in which it has orphan drug status in the U.S. Away from rare diseases, Pfizer dropped a midphase rheumatoid arthritis candidate, ritlecitinib, and a trio of phase 2 cancer programs. Ritlecitinib is closing in on approval decisions in alopecia areata on both sides of the Atlantic and is in phase 2 and 3 development as a treatment for vitiligo, ulcerative colitis and Crohn’s disease. But after studying the candidate with the IRAK4 inhibitor zimlovisertib and JAK inhibitor Xeljanz, Pfizer has decided to abandon plans to develop it as a treatment for rheumatoid arthritis. The three early-phase cancer candidates that failed to make the cut at Pfizer are: the therapeutic vaccine PF-07263689 in solid tumors; the BRAF kinase inhibitor PF-07284890 in melanoma; and the CDK2/4/6 inhibitor PF‑06873600 in metastatic breast cancer. Pfizer's discontinuation drive also included ending phase 3 trials for the company's blockbuster COVID-19 pill Paxlovid in standard risk populations and as a prophylactic treatment. The antiviral is already authorized in high risk populations but had flopped in a post-exposure trial.

Phase 2License out/inOrphan DrugVaccinePhase 3

09 Jan 2023

·www.prnewswire.com

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Aclaris Therapeutics [Zunsemetinib (ATI-450)], Abivax [ABX464], and others with their key candidates are in the late clinical and filing stage. LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Rheumatoid Arthritis Market Report As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021. According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4. 7 million in 2021. Leading rheumatoid arthritis companies such as Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others are developing novel rheumatoid arthritis drugs that can be available in the rheumatoid arthritis market in the coming years. The promising rheumatoid arthritis therapies in the pipeline include Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others. In June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA. In December 2021, Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research. Discover which therapies are expected to grab the major rheumatoid arthritis market share @ Rheumatoid Arthritis Market Report Rheumatoid Arthritis Overview Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown. Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis. There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs). Rheumatoid Arthritis Epidemiology Segmentation DelveInsight estimates that there were approximately 4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021. Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021 The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases Total Diagnosed Prevalent Cases Gender-specific Prevalent Cases Age-specific Prevalent Cases Severity-specific Prevalent Cases Patients on Targeted Therapies Line-Wise Treated Cases Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights Rheumatoid Arthritis Treatment Market Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression. Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment. Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive. To know more about rheumatoid arthritis guidelines, visit @ Rheumatoid Arthritis Management Rheumatoid Arthritis Pipeline Therapies and Key Companies Artlegia (Olokizumab): R-Pharm TS-152 (Ozoralizumab): Taisho Pharmaceuticals Otilimab (GSK3196165/MOR103): GlaxoSmithKline ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics Branebrutinib: Bristol Myers Squibb LY3462817: Eli Lilly and Company TAS5315: Taiho Pharmaceutical Rabeximod (Rob 803): Cyxone GS-5718: Gilead Sciences KPL-404: Kiniksa Pharmaceuticals MBS2320: Istesso AMT-101: Applied Molecular Transport Dazodalibep (HZN-4920): Horizon Therapeutics Cevidoplenib (SKI-O-703): Genosco/Oscotec HB-AdMSCs: Hope Biosciences ABX464: Abivax MPC-300-IV: Mesoblast PF-06650833: Pfizer JTE 051: Akros Pharma/Japan Tobacco Dekavil (F8IL10): Pfizer/Philogen ABBV-154: AbbVie PF-06651600 (Ritlecitinib): Pfizer AP1189: SynAct Pharma Learn more about the FDA-approved drugs for rheumatoid arthritis @ Drugs for Rheumatoid Arthritis Treatment Rheumatoid Arthritis Market Dynamics The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth. Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as JAKi and the upcoming BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA. However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market. In addition, the entry of biosimilars has already begun in the US and EU (i.e., Remicade biosimilars), and as a result, sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as Humira (i.e., 2023 in the US), Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market. Scope of the Rheumatoid Arthritis Market Report Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement Discover more about rheumatoid arthritis drugs in development @ Rheumatoid Arthritis Clinical Trials Table of Contents Related Reports Rheumatoid Arthritis Epidemiology Forecast Rheumatoid Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Juvenile Rheumatoid Arthritis Pipeline Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Juvenile Rheumatoid Arthritis Market Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Psoriatic Arthritis Market Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market Related Healthcare Blogs Rheumatoid Arthritis Emerging Drugs Knee Osteoarthritis Pipeline Rheumatoid Arthritis Market Scenario Juvenile Idiopathic Arthritis Therapy Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Clinical Result

100 Deals associated with Zimlovisertib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15143

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	United States	Pfizer Inc.	27 Nov 2020
Respiratory Distress Syndrome, Adult	Phase 2	United States	Pfizer Inc.	27 Nov 2020
Hidradenitis Suppurativa	Phase 2	United States	Pfizer Inc.	02 Dec 2019
Hidradenitis Suppurativa	Phase 2	Australia	Pfizer Inc.	02 Dec 2019
Hidradenitis Suppurativa	Phase 2	Canada	Pfizer Inc.	02 Dec 2019
Rheumatoid Arthritis	Phase 2	United States	Pfizer Inc.	10 Nov 2016
Rheumatoid Arthritis	Phase 2	Australia	Pfizer Inc.	10 Nov 2016
Rheumatoid Arthritis	Phase 2	Bosnia and Herzegovina	Pfizer Inc.	10 Nov 2016
Rheumatoid Arthritis	Phase 2	Bulgaria	Pfizer Inc.	10 Nov 2016
Rheumatoid Arthritis	Phase 2	Croatia	Pfizer Inc.	10 Nov 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04092452 (Pubmed \| NEJM Evid) Manual	Phase 2	Hidradenitis Suppurativa JAK1 \| TYK2	194	zimlovisertib	rhsvnkzwig(dxaafyxmzz) = bjggtgsghy owwkoihcjj (etamgfevyv ) View more	Positive	27 Feb 2024
NCT05064332 (CTgov)	Phase 1	-	10	OC (Period 1: Oral Contraceptive)	ndmrrrokcc(nrggwmzhcf) = qvtuecoivo htissbeupp (wbxmbfcjal, 25) View more	-	02 Oct 2023
				PF-06650833 (Period 2: PF-06650833 + Oral Contraceptive)	ndmrrrokcc(nrggwmzhcf) = irogllcshk htissbeupp (wbxmbfcjal, 26) View more
NCT04092452 (CTgov)	Phase 2	Hidradenitis Suppurativa	194	placebo+PF-06826647+PF-06700841+PF-06650833 (Placebo)	akeyzkqruy = oxlmeblchg nzupfwupvm (eznidkzgbg, totlythemk - fsupmobbwz) View more	-	15 Jun 2023
				PF-06650833 (PF-06650833 400mg QD)	akeyzkqruy = qmfdacxhsb nzupfwupvm (eznidkzgbg, wbljyzoflu - gnlftsctyw) View more
NCT04413617 (CTgov)	Phase 2	Rheumatoid Arthritis	460	Tofacitinib+PF-06650833 (PF-06650833 400mg MR + Tofacitinib 11mg MR)	ydnflxiqeo(ncqsdciiie) = lxcooayyjb tyzyzpqrqg (xwbjodnqbj, nsifdplbvv - sabywmfccs) View more	-	07 Apr 2023
				MR+PF-06651600+PF-06650833 (PF-06650833 400mg MR + PF-06651600 100mg)	ydnflxiqeo(ncqsdciiie) = fumzanarvn tyzyzpqrqg (xwbjodnqbj, kcxqqhrlye - jzjoxjexax) View more
NCT02996500 (CTgov)	Phase 2	Rheumatoid Arthritis	269	Placebo	tiybpdjsrg(foxzglrhad) = szobydfxdj ikemthxlci (woodpxgsvf, lcmmnivejd - hqrkwltcfw) View more	-	27 Feb 2020
NCT02224651 (Pubmed) Manual	Phase 1	-	-	PF-06650833	ufkdqxjnec(abrsotybcq) = TEAEs were generally mild in severity, with headache, gastrointestinal disorders, and acne most commonly reported. zvmctmkyhu (wjagackfgk ) View more	Positive	05 Dec 2019
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis